Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot shows promise for weight loss in type 2 diabetes

NCT ID NCT06926842

Disease control Sponsor: Zealand Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This Phase 2 trial tests a once-weekly injection called petrelintide in 221 people with overweight or obesity and type 2 diabetes. Participants receive either petrelintide or a placebo for several weeks. The main goal is to see how much weight they lose and whether blood sugar improves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
petrelintide (a once-weekly injection)
What this could lead to
If successful, this could lead to a new weekly injection that helps people with type 2 diabetes and overweight lose weight and improve blood sugar control.
What could go wrong
This is an early Phase 2 trial with only 221 people, so results may not apply to everyone. The drug may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

221 people

The number who actually took part.

Started

Apr 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Male or female participants with body mass index (BMI) ≥27.0 kg/m2. * Diagnosed with type 2 diabetes ≥180 days prior to the day of screening. * Treated with metformin with or without sodium-glucose cotransporter 2 inhibitors. Treatment should be stable (same drug\[s\], dose, and dosing frequency) for at least 90 days prior to screening. Main Exclusion Criteria: * Severe hypoglycemia within 6 months prior to screening or history of hypoglycemia unawareness. * Receipt of any other glucose-lowering drug than those listed in the inclusion criterion within 90 days prior to screening. * A self-reported change in body weight \>5% within 90 days prior to screening, irrespective of medical records. * Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 90 days prior to screening. * Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g., sleeve, banding, or similar) that have been removed more than 6 months prior to screening, are allowed. * Obesity due to endocrine disorders or genetic syndromes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Type 2 diabetes

Contacts and locations

Locations

  • AAMRC

    Flint, Michigan, 48504, United States

  • AMR Kansas City

    Kansas City, Missouri, 64114, United States

  • AZ Endocrine Institute

    Chandler, Arizona, 85224, United States

  • Centricity Research

    Columbus, Ohio, 43213, United States

  • Chase Medical Research, LLC

    Waterbury, Connecticut, 06708, United States

  • Consano Clinical Research

    Shavano Park, Texas, 78231, United States

  • Cullman Clinical Trials - Family Medicine

    Cullman, Alabama, 35055, United States

  • DelRicht Research - New Orleans

    New Orleans, Louisiana, 70115, United States

  • Diablo Clinical Research Inc.

    Walnut Creek, California, 94598, United States

  • East Coast Institute for Research - Canton

    Canton, Georgia, 30114, United States

  • East Coast Institute for Research, LLC

    Jacksonville, Florida, 32204, United States

  • Elite Clinical Studies, LLC

    Phoenix, Arizona, 85018, United States

  • Elligo Clinical Research, Inc.

    Austin, Texas, 78704, United States

  • Emerson Clinical Research

    Washington D.C., District of Columbia, 20009, United States

  • Exalt Clinical Research

    San Diego, California, 91910, United States

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640, United States

  • Heartland Research Associates, LLC

    Wichita, Kansas, 67226, United States

  • Innovative Research of West Florida

    Clearwater, Florida, 33756, United States

  • International Diabetes Center

    Minneapolis, Minnesota, 55416, United States

  • Iowa Diabetes & Endocrinology Research Center

    West Des Moines, Iowa, 50266, United States

  • Javara Inc

    Charlotte, North Carolina, 28210, United States

  • Juno Research LLC

    Houston, Texas, 77040, United States

  • Lynn Institute of Norman

    Norman, Oklahoma, 73072, United States

  • M3 Wake Research

    Raleigh, North Carolina, 27612, United States

  • M3 Wake Research - Atlanta

    Atlanta, Georgia, 30328, United States

  • M3 Wake Research - Charleston

    Charleston, South Carolina, 29414, United States

  • M3 Wake Research - Lake City

    Lake City, Florida, 32055, United States

  • M3 Wake Research - Las Vegas, NV

    Las Vegas, Nevada, 89106, United States

  • M3 Wake Research, Tucson Neuroscience Research, LLC

    Tucson, Arizona, 85710, United States

  • M3 Wake Research/ClinSearch, LLC

    Chattanooga, Tennessee, 37421, United States

  • Manaasas Clinical Research Center

    Manassas, Virginia, 20110, United States

  • Medical Investigation Inc

    Little Rock, Arkansas, 72211-1847, United States

  • Mercury Street Medical Group, PLLC

    Butte, Montana, 59701, United States

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409, United States

  • Palm Research Center, Inc.

    Las Vegas, Nevada, 89148, United States

  • PharmQuest Life Sciences, LLC

    Greensboro, North Carolina, 27408, United States

  • Privia Medical Group Georgia, LLC

    Savannah, Georgia, 31406, United States

  • Solutions Through Advanced Research, Inc

    Jacksonville, Florida, 32216, United States

  • Tekton Research, LLC

    Irving, Texas, 75039, United States

  • Tekton Research, LLC

    McKinney, Texas, 75069, United States

  • Texas Health Care

    Stephenville, Texas, 76401, United States

  • Texas Health Care, PLLC

    San Marcos, Texas, 78666, United States

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75390-8857, United States

  • Velocity Clinical Research

    Huntington Park, California, 90255, United States

  • Velocity Clinical Research, Cincinnati, Mt. Auburn

    Cincinnati, Ohio, 45219, United States

  • Velocity Clinical Research, Gulfport

    Gulfport, Mississippi, 39503, United States

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California, 91606, United States

  • West Orange Endocrinology P.A

    Ocoee, Florida, 34761, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.